Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of RPL554 on Top of Standard COPD Reliever Medications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02542254
Recruitment Status : Completed
First Posted : September 4, 2015
Last Update Posted : September 9, 2016
Sponsor:
Information provided by (Responsible Party):
Verona Pharma plc

Brief Summary:

This study evaluates the addition of RPL554 to standard reliever medications for chronic obstructive pulmonary disorder (COPD). All patients will receive the same six treatments in a randomised sequence:

  1. salbutamol,
  2. ipratropium,
  3. salbutamol + RPL554,
  4. ipratropium + RPL554,
  5. RPL554
  6. Placebo

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: Salbutamol Drug: Ipratropium Drug: RPL554 Drug: Salbutamol matched placebo Drug: Ipratropium matched placebo Drug: RPL554 matched placebo Phase 2

Detailed Description:
The purpose of this study is to investigate if RPL554 has an additive bronchodilator effect when administered in combination with standard of care bronchodilators in patients with COPD.This study investigates the pharmacodynamic effect of RPL554 using spirometry and whole body plethysmography compared to placebo, when administered in addition to a beta2 agonist (salbutamol), a muscarinic antagonist (ipratropium) or placebo.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD.
Study Start Date : October 2015
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Active Comparator: Salbutamol alone
200 micrograms salbutamol, ipratropium matched placebo and RPL554 matched placebo
Drug: Salbutamol
200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

Drug: Ipratropium matched placebo
Placebo pMDI

Drug: RPL554 matched placebo
Nebulised placebo

Experimental: Salbutamol and RPL554
200 micrograms salbutamol, ipratropium matched placebo and 6 mg RPL554
Drug: Salbutamol
200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)

Drug: RPL554
6 mg RPL554 administered using a nebuliser

Drug: Ipratropium matched placebo
Placebo pMDI

Active Comparator: Ipratropium
Salbutamol matched placebo, 40 micrograms ipratropium and RPL554 matched placebo
Drug: Ipratropium
40 micrograms ipratropium administered using a pMDI

Drug: Salbutamol matched placebo
Placebo pMDI

Drug: RPL554 matched placebo
Nebulised placebo

Experimental: Ipratropium and RPL554
Salbutamol matched placebo, 40 micrograms ipratropium and 6 mg RPL554
Drug: Ipratropium
40 micrograms ipratropium administered using a pMDI

Drug: RPL554
6 mg RPL554 administered using a nebuliser

Drug: Salbutamol matched placebo
Placebo pMDI

Experimental: RPL554
Salbutamol matched placebo, ipratropium matched placebo and 6 mg RPL554
Drug: RPL554
6 mg RPL554 administered using a nebuliser

Drug: Salbutamol matched placebo
Placebo pMDI

Drug: Ipratropium matched placebo
Placebo pMDI

Placebo Comparator: Placebo
Salbutamol matched placebo, ipratropium matched placebo and RPL554 matched placebo
Drug: Salbutamol matched placebo
Placebo pMDI

Drug: Ipratropium matched placebo
Placebo pMDI

Drug: RPL554 matched placebo
Nebulised placebo




Primary Outcome Measures :
  1. 8 hour spirometry [ Time Frame: 8 hours ]
    Forced expired volume in one second (FEV1) over 8 hours post-dose


Secondary Outcome Measures :
  1. 12 hour spirometry [ Time Frame: 12 hours ]
    FEV1 over 4, 6 and 12 hours post-dose

  2. Whole body plethysmography [ Time Frame: 4 hours ]
    Functional residual capacity, residual volume, total lung capacity, specific airway conductance, specific airway resistance at 1 and 4 hours post-dose

  3. Area under the curve (AUC) [ Time Frame: 12 hours ]
    AUC for RPL554 plasma concentration

  4. Maximum plasma concentration (Cmax) [ Time Frame: 12 hours ]
    Cmax for RPL554 plasma concentration

  5. Time to maximum plasma concentration (Tmax) [ Time Frame: 12 hours ]
    Tmax for RPL554 plasma concentration

  6. Adverse events [ Time Frame: Up to 94 days ]
    Continuous measurement of adverse events throughout the study

  7. Safety laboratory tests [ Time Frame: Up to 94 days ]
    Laboratory safety tests at screening, before each treatment and end of study

  8. ECG [ Time Frame: Up to 94 days ]
    12 lead ECG at screening, before and up to 12 hours after each treatment and end of study

  9. Vital signs [ Time Frame: Up to 94 days ]
    Blood pressure and pulse rate at screening, before and up to 12 hours after each treatment and end of study



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide informed consent
  • Males not donating sperm and using adequate contraception or females who are surgically sterile or postmenopausal
  • 12-lead ECG showing:Heart rate 45 to 90 bpm, QTcF≤450 msec, QRS ≤120 msec, PR interval ≤220 msec, no clinically significant abnormality
  • Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.
  • BMI 18 to 33 kg/m2 with a minimum weight of 45 kg.
  • COPD diagnosis for at least 1 year and clinically stable COPD in previous 4 weeks
  • Demonstrates reversibility to bronchodilator (two puffs of salbutamol followed by two puffs of ipratropium) via spirometry:

    • Post-bronchodilator FEV1/forced vital capacity (FVC) ratio of ≤0.70
    • Post-bronchodilator FEV1 ≥40 % and ≤80% of predicted normal
    • ≥150 mL increase from pre-bronchodilator FEV1
  • Chest X-ray showing no abnormalities
  • Meet the concomitant medication restrictions and be expected to do so for the rest of the study.
  • Smoking history of ≥10 pack years.
  • Capable of withdrawing from long acting bronchodilators throughout the study and short acting bronchodilators for 8 hours prior to study treatment.

Exclusion Criteria:

  • History of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
  • COPD exacerbation requiring oral steroids in the previous 3 months
  • History of one or more hospitalisations for COPD in the previous 12 months
  • Respiratory tract infection (both upper and lower) treated with antibiotics in previous 12 weeks
  • Evidence of cor pulmonale or clinically significant pulmonary hypertension.
  • Other respiratory disorders
  • Previous lung resection or lung reduction surgery.
  • Oral therapies for COPD in the previous 3 months and throughout the study.
  • Drug or alcohol abuse in the past 3 years
  • Received an experimental drug within 3 months or five half lives, whichever is longer.
  • Prior exposure to RPL554
  • Patients with a history of chronic uncontrolled disease that the Investigator believes are clinically significant.
  • Documented cardiovascular disease in last 3 months
  • Major surgery, (requiring general anaesthesia) in the previous 6 weeks, or will not have fully recovered from surgery, or planned surgery through the end of the study.
  • History of malignancy of any organ system within 5 years with the exception of localised skin cancers (basal or squamous cell)
  • Clinically significant abnormal values for safety laboratory tests
  • A disclosed history, or one known to the Investigator, of significant non compliance in previous investigational studies or with prescribed medications.
  • Requires oxygen therapy, even on an occasional basis.
  • Inability to adequately perform whole body plethysmography.
  • Any other reason that the Investigator considers makes the subject unsuitable to participate.
  • Patients with known hypersensitivity to atropine or its derivatives, or to ipratropium bromide, salbutamol or RPL554 or their excipients/components.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02542254


Locations
Layout table for location information
United Kingdom
Medicines Evaluation Unit
Manchester, United Kingdom
Sponsors and Collaborators
Verona Pharma plc
Investigators
Layout table for investigator information
Principal Investigator: Dave Singh Medicines Evaluation Unit

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Verona Pharma plc
ClinicalTrials.gov Identifier: NCT02542254     History of Changes
Other Study ID Numbers: RPL554-009-2015
2015-002536-41 ( EudraCT Number )
First Posted: September 4, 2015    Key Record Dates
Last Update Posted: September 9, 2016
Last Verified: September 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Ipratropium
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Lung Diseases
Respiratory Tract Diseases
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Cholinergic Antagonists
Cholinergic Agents